Malpractice coverage is one of the practical concerns that most often slows providers’ movement into the two-hat model. The concern is reasonable. Cannabis evaluation work is not yet covered by all standard medical malpractice carriers, and the coverage that does exist varies in scope and quality. Understanding the landscape lets providers structure their coverage correctly before they start, rather than discovering gaps after.
The two coverage questions
A two-hat provider needs answers to two distinct malpractice questions. First: does the existing malpractice coverage on the federal practice cover cannabis evaluation work? Second: if not, what coverage is available for the cannabis evaluation practice, and on what terms? The answers vary by carrier, state, and specialty, and they need to be confirmed in writing with the carrier rather than assumed.
Why this is not a standard coverage question
Standard medical malpractice policies were not designed with state-legal cannabis evaluation in mind. Many policies have language excluding coverage for federally illegal acts, or for acts outside the scope of state-licensed practice, or for acts the carrier could not assess actuarially when the policy was written. None of this language was directed at cannabis evaluation specifically — the policies pre-date the widespread emergence of state medical cannabis programs — but the language is what carriers point to when claims related to cannabis work come up.
Does the existing federal-practice policy cover cannabis evaluation work?
In most cases, no — or at least, not reliably. Standard medical malpractice carriers have responded to the emergence of cannabis evaluation work in varied ways. Some have written explicit exclusions into renewal policies. Some have remained silent, leaving the coverage question unresolved until a claim arises. A small number have added cannabis evaluation as a covered activity, either by default or as an opt-in endorsement.
The way to find out for any specific policy is direct: write to the carrier (in writing, with a copy retained) and ask whether the policy covers state-licensed cannabis evaluation work conducted under a separate state cannabis recommendation registration. Ask for the answer in writing. Do not rely on phone-call reassurances; carrier representatives sometimes give informal answers that the carrier’s claims department later contradicts.
Specialty cannabis evaluation coverage
A growing number of specialty carriers now write coverage specifically for cannabis evaluation practice. The coverage is structured around the activities the practice actually performs: clinical evaluation of patients for state cannabis programs, attestation of qualifying conditions, documentation of recommendations, and the ancillary clinical services that surround the evaluation work. Premiums vary by state, by specialty, and by claims volume in the carrier’s book of business, but the order of magnitude is comparable to standard medical malpractice for a focused outpatient practice.
Specialty carriers worth investigating for cannabis evaluation coverage include carriers that have built dedicated cannabis healthcare practice lines, as well as some general medical malpractice carriers that have added cannabis endorsements to their standard policies. The landscape changes quickly enough that any specific recommendation in this guide would become stale; the right approach is to consult with a healthcare-specialized insurance broker who can survey current options for your state and specialty.
What to ask any carrier
Whether evaluating a new policy or confirming coverage on an existing one, the questions to ask are concrete. Does the policy cover cannabis evaluation work conducted under a state recommendation registration? Does it cover the documentation and attestation activities specific to state cannabis programs? Does it cover claims arising from the patient’s subsequent cannabis use, or only from the evaluation itself? What are the exclusions? What is the tail coverage if the policy is later canceled or not renewed?
The actual malpractice exposure of cannabis evaluation
The malpractice claim picture for cannabis evaluation work is, in actuarial terms, lower-volume and less severe than many other specialty practice types. The reasons make sense when examined honestly:
- The evaluation does not involve procedures. Cannabis evaluations are clinical history, examination, and documentation. The procedural risks that drive malpractice claims in many specialties are absent.
- The provider does not control dosing or supply. The cannabis itself comes from state-licensed dispensaries operating under state rules. The provider is not prescribing specific products or managing dose titration in the way prescription medication practice does.
- The clinical question is structured. The state programs define qualifying conditions and evaluation requirements. The clinical decision-making operates within a framework the state has set, which makes the standard of care more defined than in some open-ended specialties.
- The patient relationship is typically episodic. Most cannabis evaluation patients are seen for the evaluation and renewals, not for ongoing primary care management. The longitudinal complexity that drives many primary care malpractice claims is reduced.
Where exposure actually concentrates
The cannabis evaluation claims that do occur cluster in a few predictable patterns. Understanding these patterns lets providers structure their practice to minimize exposure.
Documentation gaps
The largest single source of cannabis evaluation claims is incomplete documentation.
A patient with an adverse outcome whose evaluation record does not adequately document the qualifying condition assessment, the risk-benefit discussion, or the patient’s understanding of the recommendation creates a defensibility problem that has nothing to do with the clinical judgment exercised. Documentation completeness is the single most effective risk management practice in the cannabis evaluation context. Each evaluation should document the qualifying condition assessment, the medical history review, the risk-benefit discussion, the patient’s questions and the provider’s responses, and the recommendation outcome.
Inappropriate qualifying condition attestations
Recommending cannabis for a condition that does not actually meet the state’s qualifying criteria.
Providers who write recommendations for conditions outside the state’s qualifying list, or who stretch the qualifying language inappropriately, create exposure both regulatory and malpractice. The standard is the state’s standard. Recommendations within that standard are defensible; recommendations outside it are not.
Drug interaction failures
Recommending cannabis without adequate review of the patient’s other medications.
Cannabis interacts with a range of commonly prescribed medications, particularly anticoagulants, certain antidepressants, and CNS depressants. A patient harmed by an interaction the evaluation should have surfaced creates exposure that adequate medication review would have prevented. Veterans, who often take multiple medications managed by VA care, deserve particular care in this review.
Failure to address contraindications
Recommending cannabis where contraindications exist.
Certain patient histories — significant psychotic disorders, certain cardiovascular conditions, active substance use disorders — create contraindications that the evaluation should identify. Providers who recommend without addressing these create exposure that careful evaluation would have avoided.
The two-policy structure
Most two-hat providers operate with two separate malpractice policies — one covering the federal practice (typically through the standard medical malpractice carrier the provider already uses), one covering the cannabis evaluation practice (typically through a specialty carrier or an endorsement). The premium for the cannabis evaluation policy adds to the practice’s administrative cost but is not, in most cases, dramatically larger than a focused specialty policy would be.
The two policies stay separate the way the practices stay separate: separate applications, separate renewals, separate financial flows, separate claim reporting. A claim arising from cannabis evaluation work is reported to the cannabis evaluation carrier under that policy. A claim arising from federal-practice work is reported to the federal-practice carrier. The structure mirrors the operational structure of the model itself.
The conversation worth having with your broker
Before entering the two-hat model, providers should have a structured conversation with a healthcare-specialized insurance broker who understands the landscape. The conversation should cover:
- Current carrier’s position on cannabis evaluation work
- Available specialty carrier options for the cannabis evaluation practice
- State-specific considerations affecting coverage availability
- The exclusions to look for in any policy
- The tail coverage implications of either practice ending later
- How the two policies coordinate (or don’t) if a claim implicates both practices
The conversation typically takes ninety minutes and produces a concrete coverage plan that the provider can implement before seeing the first cannabis evaluation patient. Providers who skip this conversation and discover the coverage gap later have one of the more painful surprises the model can produce.
The honest summary
Cannabis evaluation work is insurable. The coverage market is real, growing, and accessible to providers who approach it deliberately. The malpractice exposure of the evaluation work itself is, in actuarial terms, lower than many specialty practice types. The risk management work that matters most is documentation discipline within each evaluation. None of this eliminates the need for serious upfront attention to coverage; all of it makes the coverage question workable rather than disqualifying.